Infinity Pharmaceuticals, Inc. ( INFI) Stock. Should you Buy or Sell? $ 1.49
-0.02 (-1.36 %)
Infinity Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | INFI |
| Price | $1.49 |
| Beta | 1.996 |
| Volume Avg. | $734.71 thousand |
| Market Cap | $133.02 M |
| 52 Week Range | $0.46 - $3.77 |
Infinity Pharmaceuticals, Inc. opened the day at $1.49 which is -1.36 % on yesterday's close. Infinity Pharmaceuticals, Inc. has a 52 week high of $3.77 and 52 week low of $0.46, which is a difference of $3.31. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $133.02 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Infinity Pharmaceuticals, Inc. for $133.02 M, it would take 15 years to get your money back. Infinity Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Infinity Pharmaceuticals, Inc. Stock Forecast - Is Infinity Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Strong Buy | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -2.884 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -28.938 |
Valuing Infinity Pharmaceuticals, Inc.
| Price Book Value Ratio | 13.308 | Price To Book Ratio | 13.308 |
| Price To Sales Ratio | 83.443 | Price Earnings Ratio | -2.884 |
How liquid is Infinity Pharmaceuticals, Inc.
| Current Ratio | 5.234 |
| Quick Ratio | 5.013 |
Debt
| Debt Ratio | 0.862 | Debt Equity Ratio | 6.271 |
| Long Term Debt To Capitalization | 0.072 | Total Debt To Capitalization | 0.116 |
Latest news about Infinity Pharmaceuticals, Inc.
Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Second Quarter 2022 Financial Results and Business Update.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and CEO Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Anupam Rama - JPMorgan Nick Abbott - Wells Fargo Soumit Roy - Jones Research Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the company's operations and First Quarter 2022 Financial Results.
Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript
About Infinity Pharmaceuticals, Inc.
Description :
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
